B cells and cancer: To B or not to B?

117Citations
Citations of this article
231Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact.

Cite

CITATION STYLE

APA

Fridman, W. H., Petitprez, F., Meylan, M., Chen, T. W. W., Sun, C. M., Roumenina, L. T., & Sautès-Fridman, C. (2021). B cells and cancer: To B or not to B? Journal of Experimental Medicine. Rockefeller University Press. https://doi.org/10.1084/JEM.20200851

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free